Clinical trial · Observational
Diagnostic and Management Strategies for Invasive Aspergillosis
Diagnostic and Management Strategies for Invasive Aspergillosis in Neutropenic Adult Haemato-Oncology Patients With a Proposal for Investigation of a Novel Potential Marker for Early Diagnosis: a Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fungal infections caused by Aspergillus fumigatus are now identified in up to 45% of patients dying from haematological malignancy. There has been a significant increase in deaths from IA over the last 20 years. Our current diagnostic approach is neither sensitive nor specific. The purpose of this study is to prospectively assess the value of current diagnostic tools, as well as test other new diagnostic methods for the diagnosis of IA among haemato-oncology patients undergoing chemotherapy or stem cell transplantation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invasive Aspergillosis | — | UNRESOLVED | — |
| Neutropenia | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- neutropenia
- description
- Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
Primary outcomes (1)
- measure
- To determine the incidence of IFD using a comprehensive diagnostic approach
- timeFrame
- 3 years
Secondary outcomes (4)
- measure
- Evaluation of established and experimental diagnostic methods
- timeFrame
- 2-3 years
- measure
- Costing analysis
- timeFrame
- 2-3 years
- measure
- Establish the prognostic value of CT appearances in patients with IA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All adult haemato-oncology patients admitted for transplant or high dose chemotherapy and able to consent. Exclusion Criteria: * children (\< 18 years old) or inability or refusal to consent.
References
Publications (1)
- DERIVEDBuckner SL, Ceesay MM, Pagliuca A, Morgan PE, Flanagan RJ. Measurement of posaconazole, itraconazole, and hydroxyitraconazole in plasma/serum by high-performance liquid chromatography with fluorescence detection. Ther Drug Monit. 2011 Dec;33(6):735-41. doi: 10.1097/FTD.0b013e3182381bb1. PMID 22105591